La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
Stock Information for La Jolla Pharmaceutical Company
Loading
Please wait while we load your information from QuoteMedia.